Corporate Banner
Satellite Banner
Scientific Communities
Become a Member | Sign in
Home>News>This Article

Catalent Biologics Expands into ADCs through Exclusive License with Redwood Bioscience

Published: Thursday, April 11, 2013
Last Updated: Thursday, April 11, 2013
Bookmark and Share
SMARTag™ Advanced conjugation technology to be presented at BIO International.

Catalent Pharma Solutions today announced that it has acquired an exclusive license to market Redwood Bioscience’s proprietary SMARTag™ precision protein-chemical engineering technology for the development of advanced antibody-drug conjugates (ADCs). Redwood’s novel, site-specific protein modification and linker technologies enable the generation of homogenous bioconjugates engineered to enhance potency, safety and stability. Combined with Catalent’s proprietary GPEx® cell line expression system, its brand new state-of-the-art biomanufacturing Center of Excellence in Madison, Wisconsin and broad range of bioanalytical and fill-finish services, this deal marks a further expansion of Catalent’s capabilities to help customers develop more and better biologic treatments.

ADCs combine the targeted binding specificity and half-life benefits of monoclonal antibodies with the potency advantages of small molecule chemotherapy or therapeutic agents. With the FDA’s recent approval of Genentech’s T-DM1 (Kadcycla™) for metastatic breast cancer, and a large and growing list of products in clinical and pre-clinical development, ADCs are emerging as one of the fastest growing development areas in biologic anti-cancer treatment.

Redwood’s novel protein conjugation and linker technologies overcome the limitations associated with conventional protein chemistries that produce heterogeneous products with variable conjugate potency, toxicity and stability. The SMARTag technology enables site-specific, controlled drug-protein conjugation and uses only naturally occurring modifications to proteins requiring minimal cell-line engineering. Redwood’s technology provides control over conjugate configuration, generating ADCs with optimal efficacy, safety and stability. The Redwood platform also enables the use of proprietary linker chemistry that prevents systemic drug loss and increases targeted potency. Redwood has developed an array of linkers utilizing this novel chemistry, which are designed for optimal conjugation performance.

Under the terms of the agreement, Catalent will have the exclusive right to sub-license the SMARTag technology to customers and will work with Redwood to co-market the technology and support sub-license programs. As part of the collaboration, Catalent will also take a minority equity stake in Redwood, which may increase over time up to a potential acquisition.

“Our goal is to enable our biologics customers to create more and better treatments through advanced technologies and development solutions,” commented Barry Littlejohns, President of Catalent Medication Delivery Solutions “We believe that Redwood is an industry leader in site-specific conjugation. Their innovative technologies will provide significant value to our customers looking to develop next-generation ADC therapies.”

David Rabuka Ph.D., Redwood’s co-founder and Chief Scientific Officer, added, “We are very excited to be closely allied with Catalent. The technical synergy between Redwood and Catalent is a unique opportunity to provide unparalleled access to the next generation of bioconjugates."

Further Information
Access to this exclusive content is for Technology Networks Premium members only.

Join Technology Networks Premium for free access to:

  • Exclusive articles
  • Presentations from international conferences
  • Over 2,800+ scientific posters on ePosters
  • More Than 4,000+ scientific videos on LabTube
  • 35 community eNewsletters

Sign In

Forgotten your details? Click Here
If you are not a member you can join here

*Please note: By logging into you agree to accept the use of cookies. To find out more about the cookies we use and how to delete them, see our privacy policy.

Scientific News
High Throughput Mass Spectrometry-Based Screening Assay Trends
Dr John Comley provides an insight into HT MS-based screening with a focus on future user requirements and preferences.
How a Genetic Locus Protects Adult Blood-Forming Stem Cells
Mammalian imprinted Gtl2 protects adult hematopoietic stem cells by restricting metabolic activity in the cells' mitochondria.
Genetic Basis of Fatal Flu Side Effect Discovered
A group of people with fatal H1N1 flu died after their viral infections triggered a deadly hyperinflammatory disorder in susceptible individuals with gene mutations linked to the overactive immune response, according to a recent study.
New Tech Vastly Improves CRISPR/Cas9 Accuracy
A new CRISPR/Cas9 technology developed by scientists at UMass Medical School is precise enough to surgically edit DNA at nearly any genomic location, while avoiding potentially harmful off-target changes typically seen in standard CRISPR gene editing techniques.
The MaxSignal Colistin ELISA Test Kit from Bioo Scientific
Kit can help prevent the antibiotic apocalypse by keeping last resort drugs out of the food supply.
"Good" Mozzie Virus Might Hold Key to Fighting Human Disease
Australian scientists have discovered a new virus carried by one of the country’s most common pest mosquitoes.
Non-Disease Proteins Kill Brain Cells
Scientists at the forefront of cutting-edge research into neurodegenerative diseases such as Alzheimer’s and Parkinson’s have shown that the mere presence of protein aggregates may be as important as their form and identity in inducing cell death in brain tissue.
Closing the Loop on an HIV Escape Mechanism
Research team finds that protein motions regulate virus infectivity.
New Class of RNA Tumor Suppressors Identified
Two short, “housekeeping” RNA molecules block cancer growth by binding to an important cancer-associated protein called KRAS. More than a quarter of all human cancers are missing these RNAs.
Potential Treatment for Life-Threatening Viral Infections Revealed
The findings point to new therapies for Dengue, West Nile and Ebola.
Scroll Up
Scroll Down
Skyscraper Banner

Skyscraper Banner
Go to LabTube
Go to eposters
Access to the latest scientific news
Exclusive articles
Upload and share your posters on ePosters
Latest presentations and webinars
View a library of 1,800+ scientific and medical posters
2,800+ scientific and medical posters
A library of 2,500+ scientific videos on LabTube
4,000+ scientific videos